429 related articles for article (PubMed ID: 33781506)
1. CAR T Cells.
Tudor T; Binder ZA; O'Rourke DM
Neurosurg Clin N Am; 2021 Apr; 32(2):249-263. PubMed ID: 33781506
[TBL] [Abstract][Full Text] [Related]
2. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
3. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
[TBL] [Abstract][Full Text] [Related]
4. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
Front Immunol; 2020; 11():594271. PubMed ID: 33224149
[TBL] [Abstract][Full Text] [Related]
6. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
Zhou S; Sun H; Choi SI; Yin J
Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
[TBL] [Abstract][Full Text] [Related]
7. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
8. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Salinas RD; Durgin JS; O'Rourke DM
CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
[TBL] [Abstract][Full Text] [Related]
9. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
Prinzing BL; Gottschalk SM; Krenciute G
Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
11. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight.
Land CA; Musich PR; Haydar D; Krenciute G; Xie Q
J Transl Med; 2020 Nov; 18(1):428. PubMed ID: 33176788
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
Feldman L; Brown C; Badie B
Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
Verma A; Rafiq S
Cancer Treat Res; 2022; 183():161-184. PubMed ID: 35551659
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
[TBL] [Abstract][Full Text] [Related]
16. Prospective approaches to enhancing CAR T cell therapy for glioblastoma.
Choi SI; Yin J
Front Immunol; 2022; 13():1008751. PubMed ID: 36275671
[TBL] [Abstract][Full Text] [Related]
17. Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
Jindal V
Mol Neurobiol; 2018 Nov; 55(11):8236-8242. PubMed ID: 29524050
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
Feldman L; Brown C; Badie B
Neuromolecular Med; 2022 Mar; 24(1):35-40. PubMed ID: 34665390
[TBL] [Abstract][Full Text] [Related]
19. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
20. Optimizing CAR-T Therapy for Glioblastoma.
Tang OY; Binder ZA; O'Rourke DM; Bagley SJ
Mol Diagn Ther; 2023 Nov; 27(6):643-660. PubMed ID: 37700186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
